A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
A phase 1/2 trial of TERN-701 in chronic myeloid leukaemia, run by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), now recruiting.
Overview
A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL) is a phase 1/2 interventional study registered as NCT06163430 by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), with 180 participants planned, started 2024-03-26 and due to reach its primary completion in 2029-11-30. Interventions recorded: TERN-701.
Similar pages
not linked directly; found by shared links- TrialA Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialTGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialThe Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialStudy to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialAsciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialOpen-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialStudy to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialSafety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.